Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
about
Cytomegalovirus antivirals and development of improved animal modelsLeflunomide: a drug with a potential beyond rheumatologyThe combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replicationLeflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation.BK Virus-associated Hemorrhagic Cystitis in Patients with Allogeneic Hematopoietic Cell Transplantation: Report of Three CasesUse of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus.Antivirals for the treatment of polyomavirus BK replication.Prevention and management of cytomegalovirus infection in solid-organ transplantation.Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.Leflunomide in renal transplantation.Leflunomide for cytomegalovirus: bench to bedside.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature.Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.Leflunomide in the Treatment of a Pseudotumoral Genital Herpes Simplex Virus Infection in an HIV Patient.Stabilization of renal function after the first year of follow-up in kidney transplant recipients treated for significant BK polyomavirus infection or BK polyomavirus-associated nephropathy.Contrasting patterns of viral load response in transplant recipients with BK polyomavirus DNAemia on leflunomide therapy.Leflunomide use in a cytomegalovirus infection of a patient with dermatomyositis.
P2860
Q27000998-C040693D-3D79-400F-A429-036C06FC26A6Q28294236-CFE36348-ECE8-4914-8543-5F4DD3DC10F7Q28545087-7315DCA5-B595-44C3-9910-96B590E14F9FQ33376066-B5774EA7-36AD-4CAC-8305-3C0F8869E8C1Q33863365-258254D0-A71C-4B1A-9C16-614A1E11D109Q35592509-7CB9B09C-65F1-4C51-A99B-30CB6E8B9E3BQ36686842-F88ED82B-AB1C-4BCB-9AD4-5690207575EBQ36723806-8D129F1D-A65D-41A3-A608-85D709C34705Q36777860-047944AE-656C-4906-8F79-362C3A8EB95BQ36887749-B173401B-B98D-46F0-9B78-BF65566D8C56Q37877256-012A5AC2-C7D2-4A55-8BC6-0DC17A2BBD23Q37957446-4457F778-28E7-43BA-AFA5-4264D57FB725Q38061056-845439A1-9BCC-44D4-AD50-9DB97BE9F8C5Q39155699-BC2B7FEA-B0AC-47BF-B491-E601A619E34DQ40175806-2FDB2017-0E44-492A-A46A-C0824FB5D12EQ40259798-75092B9E-BBBC-4B14-BF05-0DCC91C25AE6Q40329754-C8EE7970-C1C7-460B-988D-CC3E9B8F4837Q42268339-08B0E9F3-96FC-4337-8DCB-44A4DE01AEB9Q44945549-AEA1F1A7-85FB-4E21-AEA0-212A304FFADB
P2860
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
@en
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
@nl
type
label
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
@en
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
@nl
prefLabel
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
@en
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
@nl
P2093
P2860
P1476
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
@en
P2093
Meister GT
Waldman WJ
Williams JW
P2860
P356
10.1111/J.1600-6143.2005.01152.X
P407
P577
2006-01-01T00:00:00Z